These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. Gui J; Wang F; Hong CY; Li JL; Liang J Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731 [TBL] [Abstract][Full Text] [Related]
3. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Boulet B; Plaunt M; Brown BA; Wallace RJ; Wanger A J Clin Microbiol; 2000 Feb; 38(2):656-61. PubMed ID: 10655363 [TBL] [Abstract][Full Text] [Related]
4. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306 [TBL] [Abstract][Full Text] [Related]
5. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum. Barrett MS; Jones RN; Erwin ME; Koontz FP Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum. Hoffner SE; Klintz L; Olsson-Liljequist B; Bolmström A J Clin Microbiol; 1994 Aug; 32(8):1846-9. PubMed ID: 7989530 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria]. Özkarataş MH; Arslan N; Esen N; Özkütük AA Mikrobiyol Bul; 2023 Apr; 57(2):220-237. PubMed ID: 37067207 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990 [TBL] [Abstract][Full Text] [Related]
16. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Abshire R; Cockrum P; Crider J; Schlech B Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942 [TBL] [Abstract][Full Text] [Related]
17. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Tebas P; Sultan F; Wallace RJ; Fraser V Clin Infect Dis; 1995 Feb; 20(2):443-4. PubMed ID: 7742453 [TBL] [Abstract][Full Text] [Related]
18. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. Wallace RJ; Swenson JM; Silcox VA; Bullen MG J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. Hatakeyama S; Ohama Y; Okazaki M; Nukui Y; Moriya K BMC Infect Dis; 2017 Mar; 17(1):197. PubMed ID: 28270102 [TBL] [Abstract][Full Text] [Related]
20. Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela. Da Mata-Jardín O; Angulo A; Rodríguez M; Fernández-Figueiras S; de Waard JH Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):433-441. PubMed ID: 31741101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]